- 24/7 Technology,Internet,Bio Patent and Intellectual Property News & Information Service
-
SUBSCRIBE TO FEED
- Who are patent attorneys?
- What are patents, and how long are they in force?
- Valuing patents
- Steps in the Patent Process
- Intellectual Property and patents thereof
- History of Patents and Patent Law
- Copyrights & Copyright Law History
- Historically Famous U.S. patents
- Comparing Patents & Copyrights
- Applying for a Patent? Follow these steps
-
Articles
'Clinical' Tag
-
FDA can promote personalized medicine: ACLA
July 17, 2010[Story ID: 2962] The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation’s leading clinical laboratories, says that the factors supporting this approach include the [...]
-
Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure
June 30, 2010[Story ID: 2566] Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular diseases, today announces positive safety data and preliminary efficacy results from its clinical trial of C-Cure(R), a breakthrough stem cell therapy for heart failure.
-
Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia
June 24, 2010[Story ID: 2481] Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.
-
First clinical data for ImmunoGens IMGN388 anticancer compound presented at ASCO Annual Meeting
June 8, 2010[Story ID: 2205] ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of the first clinical data for the Company’s IMGN388 anticancer compound at the 2010 Annual Meeting of the American Society of Clinical Oncology being held in Chicago, IL.
-
Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC
June 7, 2010[Story ID: 2188] Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518, a monoclonal antibody directed against interleukin-6 (IL-6).
-
ChemGenex reports positive safety findings from two OMAPRO clinical trials at ASCO 2010
June 7, 2010[Story ID: 2191] ChemGenex Pharmaceuticals Limited announced that positive safety findings from a combined analysis of two clinical trials for its lead product candidate, OMAPRO’
-
Obesity is a risk factor for depressive symptoms
May 25, 2010[Story ID: 1998] Researchers, led by Kerri Boutelle, PhD, associate professor of pediatrics and psychiatry at the University of California, San Diego School of Medicine have found that obesity is a risk factor for depressive symptoms, but not for clinical depression, suggesting that weight status could play a part in the development of depression in [...]
-
ImaginAb, GSK CIC conclude two research collaboration agreements
May 20, 2010[Story ID: 1913] ImaginAb, Inc. and the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group of Companies) have concluded two research collaboration agreements around a clinical therapeutic antibody asset currently under development by GSK in the field of oncology.
-
Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor
May 15, 2010[Story ID: 1850] Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, [...]
-
Latest version of Phase Forward CDC released
May 5, 2010[Story ID: 1674] Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the latest version of the Phase Forward Clinical Development Center, a centralized solution for integrating, managing and analyzing clinical information.